Samsung Biologics: $2.2 Billion Rights Offering a Preemptive Move to Complete 2034 Investment Plan — BigGo Finance
Samsung Biologics reaffirmed that its approximately 3 trillion won rights offering is a preemptive measure to complete a…
Samsung Biologics Quarterly Revenue Tops ₩1.3 Trillion for First Time; Operating Profit Surges 23% — BigGo Finance
Samsung Biologics shattered its quarterly revenue record, surpassing ₩1.3 trillion (approximately $885.9 million) for the first time since…
Samsung Biologics Q2 Operating Profit Hits ₩586.4 Billion (approximately $397.2 Million), Up 23% YoY — BigGo Finance
Samsung Biologics (207940) posted second-quarter consolidated revenue of ₩1.32 trillion (approximately $894.7 million) and operating profit of ₩586.4…
Samsung Bioepis, Samsung Medical Center Team Up for AI-Based Drug Target Discovery
Samsung Bioepis President Kim Kyung-ah (left) and Samsung Medical Center Director Park Seung-woo pose for a photo after…